

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
30 May 2003 (30.05.2003)

PCT

(10) International Publication Number
WO 03/043626 A1

(51) International Patent Classification: **A61K 31/198**

PIERZYNOWSKI, Stefan [SE/SE]; Lovisastigen 50,
S-221 41 Lund (SE).

(21) International Application Number: **PCT/SE02/02123**

(22) International Filing Date:
22 November 2002 (22.11.2002)

(74) Agents: **DAHLENBORG, Katarina** et al.; Albihns
Malmö AB, P.O. Box 4289, S-203 14 Malmö (SE).

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0103932-0 23 November 2001 (23.11.2001) SE
0104385-0 21 December 2001 (21.12.2001) SE
0201713-5 6 June 2002 (06.06.2002) SE

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE,
SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US,
UZ, VC, VN, YU, ZA, ZM, ZW.

(71) Applicant (for all designated States except US): **GRAM-
INEER INTERNATIONAL AB** [SE/SE]; Scheelevägen
17, Ideon, S-223 70 Lund (SE).

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK,
TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).


(72) Inventors; and

(75) Inventors/Applicants (for US only): **STUDZINSKI,
Tadeusz** [PL/PL]; ul. Lubartowska 9/7, PL-20-115
Lublin (PL). **VALVERDE PIEDRA, Jose, Luis** [PL/PL];
ul. Swietochowskiego 149, PL-20-441 Lublin (PL).

Published:
— with international search report

[Continued on next page]

(54) Title: **USE OF GLUTAMATE, GLUTAMATE DERIVATIVES OR METABOLITES, GLUTAMATE ANALOGUES OR MIX-
TURES THEREOF FOR THE MANUFACTURE OF A COMPOSITION FOR THE TREATMENT OF OSTEOPOROSIS**



(57) Abstract: A method for obtaining improved bone quality in a vertebrate, including mammal and bird, the method comprising administering to a vertebrate, including mammal and bird, in a sufficient amount and/or at a sufficient rate to enable a desired effect, glutamate, glutamate derivatives or metabolites, glutamate analogues or mixtures thereof. Also contemplated is a method for modulating bone quality in a vertebrate, including mammal and bird, comprising administering to the vertebrate, including mammal and bird, in the need thereof, glutamate, glutamate derivatives or metabolites, glutamate analogues or mixtures thereof, for modulating the bone quality as well as a compositions for use in treatment.

WO 03/043626 A1



For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Use of glutamate, glutamate derivatives or metabolites, glutamate analogues or mixtures thereof for the manufacture of a composition for the treatment of osteoporosis.

TECHNICAL FIELD

This invention relates to a method for obtaining improved bone quality in a vertebrate, including mammal and bird. Also contemplated is a method for modulating bone quality in a vertebrate, including mammal and bird, and the manufacture of a composition for the improvement of bone quality in said vertebrate.

10 BACKGROUND OF THE INVENTION

The skeleton

The skeleton is a complex organ system that is in a constant state of flux. It serves mechanical, metabolic, and protective functions. There are two types of bone; cortical and cancellous. Cortical bone is found primarily in the shafts of the long bones of the appendicular skeleton. It is also found in the outer layer of virtually all bones. Cancellous bone is found primarily in the bones of the axial skeleton and in the ends of the long bones. The cellular process of bone activity through which both cortical and cancellous bone are maintained, is referred to as bone remodelling. This remodelling takes place on bone surfaces in discrete packets known as basic multicellular units (Parfitt et al., (1987) Clin. Obstet. Gynecol. 30:786-811).

There are numerous systemic hormones, such as parathyroid hormone and vitamins such as vitamin D, calcitonin, estrogens, androgens, as well as a number of local factors, such as interleukins, transforming growth factors and prostaglandins, that play an important role in the physiology of bone remodelling.

Skeletal disorders

Many factors contribute to the strength of the skeleton and its ability to withstand trauma without fracture. The major factor accounting for at least 70% of bone strength is bone mineral density (mass per volume). Approximately 80% of the total skeletal mass is cortical (compact) bone with a low surface: volume ratio while remaining 20% is cancellous (spongy) bone with a much higher surface: volume ratio. Alterations in the interrelationship between mass, volume, surface, and architecture are all considered in the loss of bone strength. Such a loss in bone strength will lead to an increased risk of fracture, which is one of the hallmarks of osteoporosis.

Skeletal disorders lead to a loss or weakening in bones, a condition generally termed osteoporosis.

Osteoporosis

Osteoporosis is a condition with decreased bone mass and changes in the microarchitecture of the bone, which leads to decreased strength and an increased risk for fracture.

- 5 Osteoporosis is one of the few medical conditions that affects virtually every member of the human species living beyond the age of 35. It is a major medical problem with rising medical, social, and economical consequences. Over 8 million Americans suffer from osteoporotic fractures, although the number of affected individuals is estimated to 14-25 millions using newer definitions of osteoporosis, 10 which include those who have not yet experienced fractures but have sufficiently low bone mass to place them in potential risk groups.

- The National Osteoporosis Foundation, USA, has given estimates that the cost of treating osteoporosis in 1990 was \$10 billion. With the aging of the population and the increasing prevalence of osteoporosis, medical costs alone is 15 predicted to reach \$30-45 billion before the year 2020 in the USA only. The World Health Organisation has proclaimed the decade 2000-2010 as the Decade of Bone and Joint Diseases.

- Current therapies for treatment of osteoporosis usually acts by a mechanism of increased formation or decreased resorption of bone material. The effects of such 20 treatments are summarised in table 1. Other proposed means of treating osteoporosis include calcium, exercise, and growth hormones.

Table 1 Common osteoporosis therapy strategies

Strategy	Decrease resorption	Increase formation
Effect on bone mass	Stabilize	Increase
Effect on bone cells	Decrease osteoclast activity	Increase osteoblast activity
Examples	Estrogen, calcitonin, bisphosphonates	Fluoride, Vitamin D, parathyroid hormone (PTH)

25 *Medical causes of osteoporosis*

Different medical disorders may, as a secondary effect, also lead to osteoporosis. Such medical disorders are listed in Table 2.

Table 2 Different medical disorders causing osteoporosis

	Multiple myeloma	<i>Pharmacologic agents</i>
<i>Renal</i>	Waldenstrom's	Aluminium-containing
Renal failure	macroglobulinemia	antacids
Idiopathic hypercalciuria	Systemic mastocytosis	Anticonvulsants
Renal tubular acidosis	Hemolytic anemias	Cisplatin
	Sickle cell disease	Cyclosporine
	Beta-thalassemia	Glucocorticoids
<i>Endocrine/metabolic</i>	PTHrP-secreting solid	Heparin
Diabetes mellitus type I	tumours (esp. squamous)	Methotrexate
Cushing's syndrome	renal, bladder, ovarian)	Plicamycin
Hypogonadism - primary	<i>Gastrointestinal</i>	Thyroid hormone excess
and secondary	Inflammatory bowel disease	Diuretics except thiazides
Hyperparathyroidism -	Gluten enteropathy	Alcohol
primary and secondary	Postgastrectomy	<i>Other</i>
Hyperthyroidism	Primary biliary cirrhosis	Immobilization
Homocystinuria	Hepatic insufficiency	Osteogenesis imperfecta
Acromegaly	Hemochromatosis	Disuse/paralysis
Hypovitaminosis D	Wilson's disease	Ehlers-Danlos syndrome
Scurvy	Malnutrition	Marfans syndrome
<i>Hematologic/oncologic</i>	<i>Chronic inflammatory</i>	Post organ transplantation
Leukemia	<i>diseases</i>	Pregnancy
Lymphoma	Rheumatoid arthritis	Gaucher's disease

Postmenopausal bone loss

- The last decade, the significance and consequence of postmenopausal bone loss have been identified and defined at an international level. Medical and governmental authorities have recognised the morbidity and mortality in untreated individuals as well as the financial consequence to the society.

Known treatment of osteoporosis

- Few drugs are currently known to increase bone formation. The most commonly used and studied drug is fluoride, being able to affect both bone formation and resorption. The drug is thus widely used in modern fluorotherapy (Farley et al., Science, 222:330-332, (1983), and Gruber et al., Clin. Orthop., 267:264-267), and sodium fluoride is the most evaluated form.

- Several studies show an increase in trabecular bone mass after long-term administration of fluoride and calcium. The combination of fluoride and calcium is considered as an established treatment.

Flouride based drugs, where monofluorophosphate represents the most advanced drug for fluorotherapy, show several drawbacks and often lead to complications in treated patients, e.g. gastrointestinal and rheumatic complications.

Affinito et al. have in Gynecol. Endocrinol. (7:201-205, (1993)) published a study showing an increase of 4.25% in bone mineral density after treatment of postmenopausal women with yet another form of a flouride based drug, i.e. L-glutamine calcium monofluorophosphate.

Bone problems in birds

In chickens, hens and other broilers, such as turkeys, the weight-carrying capacity of the legs is a problem. Specifically, in several lines of turkeys gaining a body weight of more than 25 kilos bone fracture is a problem. To prevent such problems that cause unnecessary suffering of the animal as well as high costs for the farmer, there is a needs for better understanding of bone growth, bone formation and bone mineralisation.

Prophylaxis

Recent trends in the prophylaxis of the skeletal diseases demand better understanding of physiological processes of the bone formation, development and mineralization during the postnatal life of a vertebrate, including mammal and bird.

Developmental concerns of the skeleton

The delivery, and the consecutive hours after, are the main source of stimuli which activate functions of the digestive system, respiratory system and motion system as a function of the gravitation and dynamic load on limb bones. Additionally, there is a differentiation during the development regarding bone mass gain, muscular mass gain and fat mass gain at various stages of life.

General nutritional status, specific nutrients (e.g., zinc, glutamine), and certain tropic growth factors (e.g., growth hormone, insulin-like growth factor I, keratinocyte growth factor, and glucagon-like peptide-2) have important interactions relevant for intestinal growth and function, which, in turn, affect the development of the limb. Adequate nutritional status is critical for endogenous growth factor synthesis in the gut and other tissues and is an important mediator of organ responsiveness to exogenous growth factor administration.

It is thus highly desirable in the light of the aforementioned problems to develop means and methods for treating or preventing any condition associated with bone loss or weakening, which can also avoid problems associated with prior art means and methods. In this respect, the present invention addresses this need and interest.

SUMMARY OF THE INVENTION

In view of the foregoing disadvantages known in the art of preventing and alleviating poor bone quality and the high medical costs for doing so, as well as for
5 correcting bone fracture associated with e.g. osteoporosis, the present invention provides new and improved methods and compositions for improving bone quality.

An object of the present invention is to provide a method for obtaining improved bone quality in a vertebrate, including mammal and bird, the method comprising administering to said vertebrate in a sufficient amount and/or at a
10 sufficient rate to enable a desired effect, glutamate, glutamate derivatives or metabolites, glutamate analogues or mixtures thereof. The a bone quality is considered improved when compared to bone quality in a vertebrate, including mammal and bird, not obtaining said glutamate, glutamate derivatives or metabolites, glutamate analogues or mixtures thereof.

Thus, the method in further embodiments include a method wherein the glutamate, glutamate derivatives or metabolites, glutamate analogues or mixtures thereof are selected from the group consisting of glutamate, alpha-ketoglutaric acid (AKG), ornithine-AKG, arginine-AKG, glutamine-AKG, glutamate-AKG, leucine-AKG and other salts of AKG with amino acids and amino acids derivatives; mono-
20 and di-metal salts of AKG such as CaAKG, NaAKG; mono- and di-metal salts of glutamate such as Ca-glutamate, Na-glutamate; glutamate dipeptides and oligopeptides e.g., L-alanyl-L-glutamate, glycyl-L-glutamate and other peptides of glutamate with amino acids; glutamate dipeptides and oligopeptides e.g., glutamate-glutamine and other peptides of glutamate with other amino acids; and glutamate
25 polymers.

The present invention also provides a method for modulating bone quality in a vertebrate, including mammal and bird, comprising administering to said vertebrate, in the need thereof, glutamate, glutamate derivatives or metabolites, glutamate analogues or mixtures thereof, for modulating the bone quality.

Still furthermore, such a method for modulating bone quality is in specific
30 embodiments a method wherein the glutamate, glutamate derivatives or metabolites, glutamate analogues or mixtures thereof are selected from the group consisting of glutamate, alpha-ketoglutaric acid (AKG), ornithine-AKG, arginine-AKG, glutamine-AKG, glutamate-AKG, leucine-AKG and other salts of AKG with amino
35 acids and amino acids derivatives; mono- and di-metal salts of AKG such as CaAKG, NaAKG; mono- and di-metal salts of glutamate such as Ca-glutamate, Na-glutamate; glutamate dipeptides and oligopeptides e.g., L-alanyl-L-glutamate, glycyl-L-glutamate and other peptides of glutamate with amino acids; glutamate

dipeptides and oligopeptides e.g., glutamate-glutamine and other peptides of glutamate with other amino acids; and glutamate polymers.

The invention further provides the use of glutamate, glutamate derivatives or metabolites, glutamate analogues or mixtures thereof, for the manufacture of a composition for the prevention, alleviation or treatment of osteoporosis.

Still furthermore, the invention provides a use of glutamate, glutamate derivatives or metabolites, glutamate analogues or mixtures thereof, for the manufacture of a composition for the modulation of bone quality in a vertebrate, including mammal and bird in the need thereof.

SHORT DESCRIPTION OF DRAWINGS

Fig. 1 is a figure showing a bone with three points marked for use in a bending test using Instron apparatus 4302,

Fig. 2 is a schematic representation of the geometrical parameters of the diaphysis of a bone showing external vertical diameter B, internal vertical diameter b, external horizontal diameter H, and internal horizontal diameter h,

Fig. 3 shows the bone ultimate strength (W_f) of humerus and femur in 35-days-old piglets when AKG is administered and where marked with an asterisk (*) $p < 0.05$,

Fig. 4 shows bone maximum elastic strength (W_y) of humerus and femur in 35-days-old piglets when AKG is administered and where marked with an asterisk (*) $p < 0.05$,

Fig. 5 shows the cross-sectional area of humerus and femur in 35-days-old piglets when AKG is administered and where marked with an asterisk (*) $p < 0.05$,

Fig. 6 shows second moment of inertia of the cross sectional area in relation to the horizontal axis (I_x) of humerus and femur in 35-days-old piglets when AKG is administered and where marked with an asterisk (*) $p < 0.05$,

Fig. 7 shows the mean relative wall thickness (MRWT) of humerus and femur in 35-days-old piglets when AKG is administered,

Fig. 8 shows second moment of inertia of the cross sectional area in relation to the horizontal axis (I_x) of ribs in 35-days-old piglets when AKG is administered and where marked with an asterisk (*) $p < 0.05$,

Fig. 9 shows the cross sectional area (A) of ribs in 35-days-old piglets when AKG is administered,

Fig. 10 shows the bone ultimate strength (W_f) of ribs in 35 days old piglets when AKG is administered and where marked with an asterisk (*) $p < 0.05$,

Fig. 11 shows the yielding stress of the 5th rib in 35-days-old piglets when AKG is administered and where marked with an asterisk (*) $p < 0.05$,

Fig. 12 shows the moment of ultimate strength of ribs in 35-days-old piglets

when AKG is administered and where marked with an asterisk (*) $p < 0.05$,

Fig. 13 shows the BMD of the ulna bone for the experimental right wing of the turkeys (grey bars) in group A treated with AKG or physiologic saline (PhS) and control left wing of the turkeys (open bars),

5 Fig. 14 shows the BMD-Wi of the ulna bone for experimental right wing of the turkeys (grey bars) in group A treated with AKG or physiologic saline (PhS) and control left wing of the turkeys (open bars),

Fig. 15 shows the BMD in intact (INT), shame operated (SHO), and ovariectomized (OVX) rats fed with (closed bars) or without AKG (open bars),

10 Fig. 16 shows the effect of oral administration of AKG on the gain of bodyweight between the AKG treated (open bars) and Ala-Gln (closed bars) treated groups during the first 47 days of postnatal life. The control group is not shown, but is always less than the Ala-Gln treated groups at the different time-points measured. On day three, the difference is about 96g, on day 14 about 690g, on day 21 about
15 419g, and on day 35 about 313g. The absolute value of the bodyweight is shown below the bars in g.

Fig. 17 shows the bone mineral density (BMD) of the right femur at the proximal and distal metaphysis at 21 days of postnatal life. AKG treated is shown in open bars and control in closed bars,

20 Fig. 18 shows the bone mineral density (BMD) of the right femur at the proximal and distal metaphysis at 35 days of postnatal life. AKG treated is shown in open bars and control in closed bars,

Fig. 19 shows the effect of AKG administration on the level of 17- β -estradiol in blood plasma of piglets measured after 3 days, 28 days, 35 days. The absolute
25 values of 17- β -estradiol in pg/ml is shown below each bar. The AKG treated is shown in open bars and the control in closed bars,

Fig. 20 shows the effect of AKG administration on the level of osteocalcin in blood plasma of piglets measured after 3 days, 28 days, 35 days, 56 days and 70 days. The absolute values of osteocalcin in ng/ml is shown below each bar. The
30 AKG treated is shown in open bars and the control in closed bars,

Fig. 21 shows the effect of Ala-Gln administration on the level of 17- β -estradiol in blood plasma of piglets measured after 3 days, 28 days, 35 days. The absolute values of 17- β -estradiol in pg/ml is shown below each bar. The Ala-Gln treated is shown in open bars and the control in closed bars, and

35 Fig. 22 shows the effect of Ala-Gln administration on the level of osteocalcin in blood plasma of piglets measured after 3 days, 28 days, 35 days, 56 days and 70 days. The absolute values of osteocalcin in ng/ml is shown below each bar. The Ala-Gln treated is shown in closed bars and the control in open bars.

DETAILED DESCRIPTION OF THE INVENTION

Definitions

As used herein, the term "bone quality" is intended to mean mechanical,
5 chemical and physiological characteristics of the bone as measured by certain
parameters used according to the invention. Such parameters are known to the
skilled man in the art and are further defined upon usage in the text

The term "improved bone quality" is herein intended to mean changes in the
mechanical, chemical and physiological characteristics of a bone, thus defining the
10 quality of the bone, compared to a vertebrate, not obtaining treatment or
administration according to the invention. The changes are regarded as an
improvement if such changes are positive for said vertebrate.

The term "modulating bone quality" is herein intended to mean changing,
modifying or otherwise influencing the current mechanical, chemical and
15 physiological characteristics of a bone.

As used herein, "pharmaceutical composition" means therapeutically
effective composition according to the invention.

A "therapeutically effective amount", or "effective amount", or
"therapeutically effective", as used herein, refers to that amount which provides a
20 therapeutic effect for a given condition and administration regimen. This is a
predetermined quantity of active material calculated to produce a desired therapeutic
effect in association with the required additive and diluent; i.e., a carrier, or
administration vehicle. Further, it is intended to mean an amount sufficient to reduce
and most preferably prevent, a clinically significant deficit in the activity, function
25 and response of the host. Alternatively, a therapeutically effective amount is
sufficient to cause an improvement in a clinically significant condition in a host. As
is appreciated by those skilled in the art, the amount of a compound may vary
depending on its specific activity. Suitable dosage amounts may contain a
predetermined quantity of active composition calculated to produce the desired
30 therapeutic effect in association with the required diluent; i.e., carrier, or additive.

As used herein, "treating", means treating for curing which may be a full
curing or a partial curing of a condition or conditions associated with bone loss or
weakening.

As used herein "alleviation", means a decreased, i.e. less, or milder condition
35 or conditions associated with bone loss or weakening.

As used herein "preventing", means a complete or partial block of develop-
ment, or outbreak, of a certain condition or conditions associated with bone loss or
weakening.

The term "derviate" or "derivative" is herein intended to mean a chemical

substance derived from mother substance either directly or by modification or partial substitution.

The term "analogue" or analog" is herein intended to mean compounds that are structurally similar to another, but are not necessarily isomers. Analogs have
5 similar function(s) but differ in structure or evolutionary origin.

In the methods and use for manufacture of compositions of the invention, a therapeutically effective amount of the active component is provided. A therapeutically effective amount can be determined by the ordinary skilled medical or veterinary worker based on patient characteristics, such as age, weight, sex,
10 condition, complications, other diseases, etc., as is well known in the art.

Bone development

The rapid growth and development of the gastro intestinal tract, GIT, and limb bones in new-born vertebrate, including mammals, such as humans and piglets,
15 and birds, such as hens and turkeys, is connected with increased intestinal requirement and cellular demand for metabolic energy supplied mainly for the enterocytes and osteocytes.

To date, no comprehensive investigation has been conducted on the nutritional effects of drugs based on glutamate, glutamate derivate, metabolites, or
20 analogues on growth, development and mineralization of the skeletal system during the postnatal period.

Glutamate derivate, metabolites, or analogues are e.g. alpha-ketoglutaric acid (AKG), and derivatives, metabolites and analogues of AKG as described and exemplified in further detail below. Flouride based drugs, such as L-glutamine
25 calcium monofluorofosphate, representing the currently used drugs for treatment of bone loss and weakening, in e.g. osteoporosis, are thus not included in the current invention. The effect, as well as side effects, of fluoride is partially different from glutamate, glutamate derivate, metabolites, or analogues.

As revealed above, the present invention relates to means and methods for
30 treating, alleviating or preventing any condition associated with bone loss or weakening. Conditions that are associated with bone loss or weakening, such as in osteoporosis, are, but not limited to, renal, such as renal failure, idiopathic hypercalciuria, renal tubular acidosis; endocrine or metabolic, such as diabetes mellitus type I, Cushing's syndrome, hypogonadism – primary and secondary,
35 hyperparathyroidism - primary and secondary, hyperthyroidism, homocystinuria, acromegaly, hypovitaminosis D, scurvy; hematologic/oncologic, such as leukemia, lymphoma, multiple myeloma, Waldenstrom's macroglobulinemia, systemic mastocytosis, hemolytic anemias, sickle cell disease, Beta-thalassemia, PTHrP-secreting solid tumours (e.g. squamous renal, bladder, ovarian); gastrointestinal,

such as inflammatory bowel disease, gluten enteropathy, postgastrectomy, primary biliary cirrhosis, hepatic insufficiency, hemochromatosis, Wilson's disease, malnutrition; chronic inflammatory diseases, such as rheumatoid arthritis; pharmacologic agents, such as aluminium-containing antacids, anticonvulsants, 5 cisplatin, cyclosporine, glucocorticoids, heparin, methotrexate, plicamycin, thyroid hormone excess, diuretics except thiazides, alcohol; and others, such as immobilization, osteogenesis imperfecta, disuse/paralysis, Ehlers-Danlos syndrome, Marfans syndrome, post organ transplantation, pregnancy, and Gaucher's disease.

10 *Bone fractures*

Bone fractures may cause so called functional osteoporosis, not only at the site of the fracture but in other bones in the body as well. Alterations in the interrelationship between mass, volume, surface, and architecture are all factors considered in the loss of bone strength. A loss in bone strength will lead to a further 15 increased risk for a fracture, which is one of the hallmarks of osteoporosis.

Other situations causing changes, e.g. loss, in bone strength are hospitalisation as in long-stay care; involuntary immobilisation, such as a human being in a wheel chair or having a plaster; voluntary immobilisation, such as a sedentary work or a sedentary life; changes in gravity field as for e.g. astronauts.

20

A method for obtaining improved bone quality

According to the invention a method is used for obtaining improved bone quality in a vertebrate, including mammal and bird, the method comprising administering to said vertebrate, in a sufficient amount and/or at a sufficient rate to 25 enable a desired effect, glutamate, glutamate derivates or metabolites, glutamate analogues or mixtures thereof, as compared to changes in a vertebrate, including mammal and bird, not obtaining said glutamate, glutamate derivates or metabolites, glutamate analogues or mixtures thereof. The changes in bone quality in the treated vertebrate is compared to changes in bone quality of a vertebrate, including mammal 30 and bird, not obtaining said glutamate, glutamate derivates or metabolites, glutamate analogues or mixtures thereof and regarded as an improvement if such changes are positive for the vertebrate, including mammals, such as a piglet or human, and birds, such as hens and turkeys, being in the need thereof.

In different embodiments of the invention, the method above is a method 35 wherein the glutamate, glutamate derivates or metabolites, glutamate analogues or mixtures thereof are selected from the group consisting of glutamate, alpha-ketoglutaric acid (AKG), ornitine-AKG, arginine-AKG, glutamine-AKG, glutamate-AKG, leucine-AKG and other salts of AKG with amino acids and amino acids derivates; mono- and di-metal salts of AKG such as CaAKG, NaAKG; mono-

and di-metal salts of glutamate such as Ca-glutamate, Na-glutamate; glutamate dipeptides and oligopeptides e.g., L-alanyl-L-glutamate, glycyl-L-glutamate and other peptides of glutamate with amino acids; glutamate dipeptides and oligopeptides e.g., glutamate-glutamine and other peptides of glutamate with other amino acids; and glutamate polymers.

In further embodiments of the invention, the vertebrate, used in the above method the vertebrate is a rodent, such as a mouse, rat, guinea pig, or a rabbit; a bird, such as a turkey, hen, chicken or other broilers; farm animals, such as a cow, a horse, a pig, piglet or free going farm animals; or a pet, such as a dog, or a cat.

In still an even further embodiment, the vertebrate is a human being. The human being may be a patient in the need of treatment of bone loss or weakening, e.g. due to osteoporosis, or due to a bone fracture. A bone fracture is a traumatic disruption of the continuity of a bone. In even further embodiments, the bone loss or weakening is due to overloading the bones, e.g., as in sport, due to overweight or a handicap.

A method for modulating bone quality

According to the invention, a method for modulating bone quality in a vertebrate, including mammal and bird, comprises administering to said vertebrate in the need thereof, glutamate, glutamate derivatives or metabolites, glutamate analogues or mixtures thereof, for modulating the bone quality.

In further embodiments of the invention, such a method for modulating bone quality is a method wherein the glutamate, glutamate derivatives or metabolites, glutamate analogues or mixtures thereof are selected from the group consisting of glutamate, alpha-ketoglutaric acid (AKG), ornitine-AKG, arginine-AKG, glutamine-AKG, glutamate-AKG, leucine-AKG and other salts of AKG with amino acids and amino acids derivatives; mono- and di-metal salts of AKG such as CaAKG, NaAKG; mono- and di-metal salts of glutamate such as Ca-glutamate, Na-glutamate; glutamate dipeptides and oligopeptides e.g., L-alanyl-L-glutamate, glycyl-L-glutamate and other peptides of glutamate with amino acids; glutamate dipeptides and oligopeptides e.g., glutamate-glutamine and other peptides of glutamate with other amino acids; and glutamate polymers.

In even further embodiments of the invention, the vertebrate, including mammal and bird, used in the above method is a rodent, such as a mouse, rat, guinea pig, or a rabbit; a bird, such as a turkey, hen, chicken or other broilers; farm animals, such as a cow, a horse, a pig, piglet or free going farm animals; or a pet, such as a dog, or a cat.

In still an even further embodiment, the vertebrate is a human being. The human being may be a patient in the need of treatment of bone loss or weakening,

e.g. due to osteoporosis, or due to a bone fracture. A bone fracture is a traumatic disruption of the continuity of a bone. In even further embodiments, the bone loss or weakening is due to overloading the bones e.g. as in sport, due to overweight or a handicap.

5

A method inhibition of bone resorption

According to the invention, a method for inhibition of bone resorption in a vertebrate, including mammal and bird, comprises administering to said vertebrate in the need thereof glutamate, glutamate derivatives or metabolites, glutamate
10 analogues or mixtures thereof, for modulating the bone quality.

In further embodiments of the invention, such a method for inhibition of bone resorption is a method wherein the glutamate, glutamate derivatives or metabolites, glutamate analogues or mixtures thereof are selected from the group consisting of glutamate, alpha-ketoglutaric acid (AKG), ornithine-AKG, arginine-AKG,
15 glutamine-AKG, glutamate-AKG, leucine-AKG and other salts of AKG with amino acids and amino acids derivatives; mono- and di-metal salts of AKG such as CaAKG, NaAKG; mono- and di-metal salts of glutamate such as Ca-glutamate, Na-glutamate; glutamate dipeptides and oligopeptides e.g., L-alanyl-L-glutamate, glycyl-L-glutamate and other peptides of glutamate with amino acids; glutamate
20 dipeptides and oligopeptides e.g., glutamate-glutamine and other peptides of glutamate with other amino acids; and glutamate polymers.

In even further embodiments of the invention, the vertebrate, including mammal and bird, used in the above method, is a rodent, such as a mouse, rat, guinea pig, or a rabbit; a bird, such as a turkey, hen, chicken or other broilers; farm
25 animals, such as a cow, a horse, a pig, piglet or free going farm animals; or a pet, such as a dog, or a cat.

In still an even further embodiment, the vertebrate is a human being. The human being may be a patient in the need of treatment of bone loss or weakening, e.g., due to osteoporosis.

30

Administration of glutamate, glutamate derivatives or metabolites, glutamate analogues or mixtures thereof

According to the methods disclosed above, glutamate, glutamate derivatives or metabolites, glutamate analogues or mixtures thereof, is administered to a
35 vertebrate, including mammal and bird; a rodent, such as a mouse, rat, guinea pig, or a rabbit; a bird, such as a turkey, hen, chicken or other broilers; farm animals, such as a cow, a horse, a pig, piglet or free going farm animals; or a pet, such as a dog, or a cat.

Administration may be performed in different ways depending on what

species of vertebrate to treat, the condition of the vertebrate in the need of said methods, and the specific indication to treat.

In one embodiment, the administration is done as a food or feed supplement, such as a dietary supplement and/or a component in form of solid food and/or
5 beverage. Further embodiments may be in the form of suspensions or solutions, such as a beverage further described below.

Also, the dosage forms may include capsules or tablets, such as chewable or soluble, e.g. effervescent tablets, as well as powder and other dry formats known to the skilled man in the art, such as pellets, such as micropellets, and grains.

10 The administration may be in the form of parenteral, rectal or oral food or feed supplement, as revealed above. Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's or fixed oils.

The food and feed supplement may also be emulsified. The active therapeutic
15 ingredient may then be mixed with excipients, which are pharmaceutically acceptable and compatible with the active ingredient. Suitable excipients are, for example, water, saline, dextrose, glycerol, ethanol, or the like and combinations thereof. In addition, if desired, the composition can contain minor amounts of auxiliary substances such as wetting or emulsifying agents, pH, buffering agents,
20 which enhance the effectiveness of the active ingredient.

Different formats of the parenteral food or feed supplement may be supplied, such as solid food, liquids or lyophilized or otherwise dried formulations. It may include diluents of various buffers (e.g., Tris-HCl, acetate, phosphate), pH and ionic strength, additives such as albumin or gelatine to prevent absorption to
25 surfaces, detergents (e.g., Tween 20, Tween80, Pluronic F68, bile acid salts), solubilizing agents (e.g., glycerol, polyethyleneglycerol), anti-oxidants (e.g., ascorbic acid, sodium metabisulfite), preservatives (e.g., Thimerosal, benzyl alcohol, parabens), bulking substances or tonicity modifiers (e.g., lactose, mannitol), covalent attachment of polymers such as polyethylene glycol to the composition,
30 complexation with metal ions, or incorporation of the material into or onto particulate preparations of polymeric compounds such as polylactic acid, polglycolic acid, hydrogels, etc., or onto liposomes, microemulsions, micelles, unilamellar or multilamellar vesicles, erythrocyte ghosts, or spheroplasts.

35 *A beverage*

In one embodiment, the food or feed supplement is administered in the form of a beverage, or a dry composition thereof, in any of the methods according to the invention.

The beverage comprises an effective amount of glutamate, glutamate

derivates or metabolites, glutamate analogues or a water-soluble innocuous salt thereof, or mixtures thereof, together with a nutritionally acceptable water-soluble carrier, such as minerals, vitamins, carbohydrates, fat and proteins. All of these components are supplied in a dried form if the beverage is provided in a dry form. A
5 beverage provided ready for consumption further comprises water. The final beverage solution may also have a controlled tonicity and acidity, e.g. as a buffered solution according to the general suggestions in the paragraph above.

The pH is preferably in the range of about 2-5, and in particularly about 2-4, to prevent bacterial and fungal growth. A sterilised beverage may also be used, with
10 a pH of about 6-8.

The beverage may be supplied alone or in combination with one or more therapeutically effective composition(s).

*Use of glutamate, glutamate derivates or metabolites, glutamate analogues or
15 mixtures thereof*

According to the invention, a use of glutamate, glutamate derivates or metabolites, glutamate analogues or mixtures thereof, are disclosed for the manufacture of a composition for the prevention, alleviation or treatment of osteoporosis.

20 Further embodiments of the invention includes a use, wherein the composition is a pharmaceutical composition. This pharmaceutical composition may be together with a pharmaceutically acceptable carrier and/or additives, such as diluents, preservatives, solubilizers, emulsifiers, adjuvants and/or carriers useful in the methods and use disclosed in the present invention.

25 Further, as used herein "pharmaceutically acceptable carriers" are well known to those skilled in the art and may include, but are not limited to, 0.01- 0.05M phosphate buffer or 0.8% saline. Additionally, such pharmaceutically acceptable carriers may be aqueous or non-aqueous solutions, suspensions, and emulsions. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol,
30 vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media. Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's or fixed oils. Preservatives and other additives may also be present, such as,
35 for example, antimicrobials, antioxidants, chelating agents, inert gases and the like.

Even further embodiments of the invention includes a use, wherein the composition is a dietary supplement and/or a component in the form of solid food and/or beverage.

Such a manufactured composition, such as a pharmaceutical composition or a

food or feed supply, comprises the use according to manufacture a composition according to the invention, and may optionally comprise a carrier and/or an amount of a second or further active ingredient affecting osteoporosis.

5 *Improving bone quality*

Still, another use according to the invention is the use of glutamate, glutamate derivates or metabolites, glutamate analogues or mixtures thereof, for the manufacture of a composition for the improvement of bone quality in a subject in the need thereof.

10 Further embodiments of the invention include a composition, wherein the composition is a pharmaceutical composition. This may be together with a pharmaceutically acceptable carrier and/or additives, such as diluents, preservatives, solubilizers, emulsifiers, adjuvants and/or carriers useful in the methods and use disclosed in the present invention.

15 Further, as used herein "pharmaceutically acceptable carriers" are well known to those skilled in the art and may include, but are not limited to, 0.01- 0.05M phosphate buffer or 0.8% saline. Additionally, such pharmaceutically acceptable carriers may be aqueous or non-aqueous solutions, suspensions, and emulsions. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol,
20 vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media. Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's or fixed oils. Preservatives and other additives may also be present, such as,
25 for example, antimicrobials, antioxidants, chelating agents, inert gases and the like.

Even further embodiments of the invention includes a use, wherein the composition is a dietary supplement and/or a component in the form of solid food and/or beverage.

Such a manufactured composition, such as a pharmaceutical composition or a
30 food or feed supply, comprises the use according to manufacture a composition according to the invention, and may optionally comprise a carrier and/or an amount of a second or further active ingredient affecting osteoporosis.

Dose of the administered pharmaceutical composition

35 According to the invention, the use of use of glutamate, glutamate derivates or metabolites, glutamate analogues or mixtures thereof for the manufacture of a composition according to the invention includes to administer a therapeutical effective amount to the vertebrat, such as a bird or mammal in the need thereof. Such a therapeutically effective amount is about 0,01-0,2 g/kg bodyweight per daily

dose.

Administration targets

As can be readily appreciated by one of ordinary skill in the art, the methods
5 and pharmaceutical compositions of the present invention are particularly suited for
administration to any animal in the need thereof, particularly a bird, including but
not limited to, a turkey, hen or chicken and other broilers and free going animals, or
a mammal, including but not limited to, domestic animals, such as feline or canine
10 subjects, farm animals, such as, but not limited to, bovine, equine, caprine, ovine,
and porcine subjects, wild animals, whether in the wild or in a zoological garden,
research animals, such as mice, rats, rabbits, goats, sheep, pigs, dogs, cats, etc., i.e.
for veterinary medical use.

Also, human beings are included as administration targets in the treatment of
bone loss or weakening, such as osteoporosis or bone fracture.

15

Use of the invention for prevention and repair of bone fractures

According to the invention, a use of glutamate, glutamate derivates or
metabolites, glutamate analogues or mixtures thereof, is included for the
manufacture of a composition for the prevention or repair of bone fractures in a
20 vertebrate, including mammal and bird, in the need thereof.

The use for the prevention or repair of bone fractures may be wherein the
composition is a pharmaceutical composition with optionally a pharmaceutically
acceptable carrier and/or additives.

Furthermore, the use for the prevention or repair of bone fractures may
25 include a composition being a food or a feed supplement, or a dietary supplement
and/or a component in form of solid food and/or beverage.

Even further embodiments include the use for the prevention or repair of
bone fractures, wherein glutamate, glutamate derivates or metabolites, glutamate
analogues or mixtures thereof, in the manufactured composition is in a
30 therapeutically effective amount. In one embodiment, the therapeutically effective
amount is 0,01-0,2 g/kg bodyweight per daily dose.

EXAMPLES

35 Example 1 The influence of L-alanyl-L-glutamine (Ala-Gln) and α -keto-glutaric
acid (AKG) on growth, development and mineralization of the skeletal system
during the postnatal life in the pig

Animal maintenance

Piglets obtained from the University herd, Czeslawice, Poland were kept in standard farming conditions.

5 Animal experiments

All piglets suckled sow milk before weaning. After weaning at the age of 28 days piglets were fed *ad libitum* with a standard mixture Premix prestarter (PP) (Food plant-Motycz, Poland) and free access to water was allowed. Piglets were allotted to three experimental trials:

- 10 1- Control group, receiving saline (2 ml/kg body weight (b.w.))
- 2- Second group, receiving 0.4 g/kg/b.w. of L-alanyl-L-glutamine (ala-gln), (2 ml solution/kg b.w.)
- 3- Third group, receiving 0.4 g/kg/b.w. α -keto-glutaric sodium salt, AKG, (2 ml solution /kg b.w.) once a day from the first day to the 35th day of life.
- 15 The experimental protocol is summarised in table 3.

Parameters for measuring bone quality

Different parameters are used for defining and measuring the bone quality according to the invention. Used parameters are known to the skilled man in the art
20 and are explained below:

- 1) Maximum elastic strength measures the load, in Newtons (N), at a fracture.
- 2) Ultimate strength measures the load, in Newtons (N), at a fracture of the bone.
- 25 3) Cross-sectional area is the measure of the bone area on the cross section, in mm².
- 4) Second moment of inertia is the measurement of the efficiency of the cross-sectional geometry to resist bending force, expressed in mm⁴.
- 5) Mean relative wall thickness is the wall thickness of the bone to its lumen.
- 30 6) Bone mineral density (BMD) expresses the mineral content of the bone expressed in g/cm².

Table 3 Experimental protocol

	Treatment	Control group (Saline)	L-alanyl- L-glutamine, (Ala-Gln group)	α - Ketoglutarate (AKG)
1 – 28 days	Sow milk +	2 ml solution /kg.bw. oral admin.	0.4 g/kg/b.w. (2 ml solution /kg b.w.) oral admin.	0.4 g/kg/b.w. (2 ml solution /kg b.w.) oral admin.
Weaning				
28 – 35 days	Premix prestarter (PP) + water ad. lib. +	2 ml solution /kg.bw. oral admin.	0.4 g/kg/b.w. Ala – gln (2 ml solution /kg b.w.) oral admin.	0.4 g/kg/b.w. (2 ml solution /kg b.w.) oral admin.
n =		8	8	7

Animal weight gain was monitored every day before oral administration of saline, ala-gln or AKG. At the age of 35 days, piglets were sacrificed, eviscerated and bones were sampled.

Architectural and geometric properties of bone were estimated based on measurements of horizontal and vertical cross section as well as interior and exterior diameter of the bone.

Using Instron 4302 apparatus and applying three point bending test as presented in figure 1, the following properties of the bones were determined from curves showing the relation between load and deflection:

- 1) maximum elastic strength, W_y
- 2) ultimate strength, W_f
- 3) bone stiffness
- 4) maximum elastic deflection.

Results

Bone properties

Bone ultimate strength, maximum elastic strength, maximum elastic deflection, bone stiffness and mean relative wall thickness (MRWT) were analysed.

Figure 2 shows a schematic representation of the geometrical parameters of the diaphysis of the bone.

Mean relative wall thickness (MRWT) expresses the ratio of wall to lumen measures and serves as an indicator in the process of architectural adaptation of

bone to physiological stress during the growth of the body. When the lumen increases with unchanged wall thickness the MRWT decreases but bone resistance to strain increases.

5 *Bone ultimate strength*

Bone ultimate strength (W_f) of humerus did not differ significantly between the control group and the Ala-Gln group, while this parameter was significantly higher in the AKG group when compared both to the piglets of the control and Ala-Gln groups (Table 4 and Figure 3).

- 10 Femur ultimate strength was the lowest in the piglets of the control group. Significantly higher values of this parameter were present in both experimental groups when compared to the control (Table 9 and Figure 3).

15 **Table 4.** Bone ultimate strength (W_f) of humerus and femur from control and experimental piglets at the age of 35 days of postnatal life

35 days	Bone ultimate strength (W_f) [N]			
	humerus		femur	
	mean± SEM		mean± SEM	
Control	747,4 ± 3,89		930,5 ± 70,23	
Ala-Gln	743,0 ± 15,71	∇	1075,0 ± 28,16	*
AKG	857,6 ± 45,42	*	1123,0 ± 75,09	*

* $p < 0,05$ AKG versus control, ∇ $p < 0,05$ AKG versus Ala-Gln

Bone maximum elastic strength

- 20 Bone maximum elastic strength (W_y) of humerus and femur of both Ala-Gln and AKG group were significantly higher in comparison to that of the control (Table 5 and Figure 4)

25 **Table 5.** Bone maximum elastic strength (W_y) of humerus and femur from control and experimental piglets at 35 days of postnatal life

35 days	Bone maximum elastic strength (W_y) [N]			
	humerus		femur	
	mean± SEM		mean± SEM	
Control	604,2 ± 26,25		921,1 ± 62,53	
Ala-Gln	638,7 ± 9,91	*	1016,8 ± 46,68	*
AKG	726,0 ± 37,73	*	1042,9 ± 73,66	*

* $p < 0,05$ experimental versus control

Cross-sectional area

Cross-sectional area (A) of humerus and femur were significantly higher in the piglets of both experimental groups when compared to that of the control (Table 6 and figure 5).

5

Table 6. Cross-sectional area (A) of humerus and femur from control and experimental piglets at 35 days of postnatal life

35 days	Cross-sectional area (A) [mm ²]	
	humerus mean± SEM	femur mean± SEM
Control	42,7 ± 3,52	49,9 ± 3,38
Ala-Gln	52,2 ± 2,48 *	60,1 ± 2,59 *
AKG	52,7 ± 4,1 *	64,7 ± 3,82 *

*p< 0,05 experimental versus control

10 *Second moment of inertia*

Second moment of inertia of the cross sectional area in relation to the horizontal axis (Ix) of humerus was significantly higher in both Ala-Gln and AKG group in comparison to control group (Table 7 and figure 6). Second moment of inertia of the femur was significantly different in the AKG group in comparison to

15 both control and Ala-Gln groups (Table 7 and figure 6).

Table 7. Second moment of inertia [mm⁴] of humerus and femur from control and experimental piglets at 35 days of postnatal life

35 days	Second moment of inertia (Ix) [mm ⁴]	
	HUMERUS mean± SEM	FEMUR mean± SEM
Control	287,5 ± 24,65	452,3 ± 49,28
Ala-Gln	368,4 ± 24,31 *	492,8 ± 12,81 ▽
AKG	459,4 ± 59,42 *	696,5 ± 48,7 *

*p< 0,05 AKG versus control, ▽p< 0,05 AKG versus Ala-Gln

20

Mean relative wall thickness

Mean relative wall thickness (MRWT) of humerus and femur of the bones of the piglets receiving Ala-Gln and AKG showed a tendency toward higher values; however, the differences were not significant (Table 8 and Figure 7).

25

Table 8. Mean relative wall thickness (MRWT) of humerus and femur from control and experimental piglets at 35 days of postnatal life

35 days	Mean Relative wall thickness (MRWT)	
	humerus	femur
	mean \pm SEM	mean \pm SEM
Control	0,52 \pm 0,09	0,62 \pm 0,06
Ala-Gln	0,64 \pm 0,07	0,88 \pm 0,12
AKG	0,57 \pm 0,08	0,70 \pm 0,07

Second moment of inertia (I_x) of the cross sectional area in relation to the horizontal axis of ribs

- Second moment of inertia (I_x) of the cross sectional area in relation to the horizontal axis of ribs was significantly higher in the AKG group when compared both to the control and Ala-Gln group. Cross sectional area of ribs in the AKG group was also significantly different in comparison to the control group. Mean relative wall thickness (MRWT) was the lowest in the ribs of piglets receiving AKG, intermediate for the control group and the highest for Ala-Gln group (Table 9 and figure 8).

Table 9. Second moment of inertia (I_x), cross-sectional area (A), mean relative wall thickness (MRWT) of ribs (4-9) of piglets at the age of 35 days of postnatal life

	Second moment of inertia [mm ⁴] (ribs 4-9)	Cross sectional area (A) [mm ²] (ribs 4-9)	MRWT (ribs 4-9)
	Mean \pm SEM	Mean \pm SEM	Mean \pm SEM
Control	10,46 \pm 0,66	9,43 \pm 0,34	0,65 \pm 0,037
Ala-Gln	10,88 \pm 0,55	9,62 \pm 0,33	0,70 \pm 0,038
AKG	15,42 \pm 0,93 *	10,52 \pm 0,35 *	0,60 \pm 0,026

* p < 0.05

15

Bone ultimate strength (W_f), maximum elastic strength and moment of ultimate strength of ribs

- Bone ultimate strength (W_f) of ribs from the 4th to the 9th was the highest in the AKG treated piglets and significantly different from that of the control group (table 10 and figure 10).

Moment of ultimate strength was significantly higher in the AKG group in comparison to both control and Ala-Gln values, which is shown in figure 12 as well as table 10.

- Maximum elastic strength (W_y) was significantly higher in the AKG group when compared to the control group (Table 10).

Cross sectional area (A) of ribs (from the 4th to the 9th) from control and experimental piglets at the age of 35 days of postnatal life is shown in figure 9, where AKG treated animals showed the largest change in area with a $p < 0.05$.

- 5 **Table 10.** Bone ultimate strength (W_f), moment of ultimate strength and bone maximum elastic strength (W_y) of 4th to 9th ribs of piglets at the age of 35 days of postnatal life

	Ultimate strength (W_f) [N] (ribs 4-9)	Moment of ultimate strength [N] ribs (4-9)	Bone maximum elastic strength (W_y)[N] (ribs 4-9)
	Mean \pm SEM	Mean \pm SEM	Mean \pm SEM
Control	463,1 \pm 23,5	612,86 \pm 32,37	423,6 \pm 18,97
Ala-Gln	450,2 \pm 22,1	625,24 \pm 1,5 ∇	442,9 \pm 15,32
AKG	585,1 \pm 18,5*	737,445 \pm 23,85*	522,5 \pm 17,97*

$p < 0.05$

- 10 *Yielding stress*

The yielding stress of the 5th rib was measured and the results for 35-days-old piglets of control and experimental groups are given in figure 11, showing a significant increase in the AKG treated group. Thus, the bones are stronger.

- 15 Example 2 The effect of AKG on the ulna mineralisation, mechanical and geometrical properties after fracture and neurectomy of the radial and medioulnar nerve in the turkey

Objective

- 20 The objective of this example is to study the effects of AKG on geometrical and physical properties of bones and callus formation and the influence of the nervous system on bone growth based on analysis of turkey wing bone (ulna).

Animal maintenance

- 25 Turkeys are kept in common cages, 10 turkeys/cage. The turkeys have free access to water and are fed *ad libitum*.

Experimental design

- 30 A total of 160 turkeys at the age of 6 weeks are divided into four experimental groups, each with a different treatment according to table 11.

Table 11 Experimental design

Group A	Right	Neurectomized – right N. radial, medioulnar	PhS ^a
		Fracture of the ulnae	AKG
	Left	Control intact	PhS
			AKG
Group B	Right ^b	Fracture of the ulnae	PhS
			AKG
	Left ^b	Control intact	PhS
			AKG
Group C	Right	Neurectomized – right N. radial, medioulnar	PhS
			AKG
	Left	Control intact	PhS
			AKG
Group D	Right	Shame operated	PhS
			AKG
	Left	Control intact	PhS
			AKG

^a PhS, physiological saline^b Right and left wing

5 Experimental performance

During general anesthetic surgery, the ulnar is broken and optionally denervated. On the first day after operation saline, AKG or Ala-Gln is administered orally at a dose of 0.8 g/kg body weight in 2 ml.

After the experimental period, the turkeys will be weighed and sacrificed in order to measure bone mineral density (BMD).

Bone mineral density (BMD) was analysed by DEXA (Dual Energy X-ray Absorptiometry) using LUNAR apparatus. The method is performed according to Hansen et al. in "Dual-energy x-ray absorptiometry: a precise method of measuring bone mineral density in the lumbar spine (J. Nucl. Med. (1990) 31: 1156-1162), incorporated herein by reference.

Results

In figure 13, BMD of the ulna bone is shown for the experimental right wing of the turkeys from group A, and the left wing control. The AKG treatment in the left wing control group gives a 25% difference ($p < 0.01$) compared to the saline treated turkeys in BMD. In the right wing experimental group, the AKG effect is about 11% ($p < 0.055$) compared to the saline treated turkeys.

In figure 14, BMD – Vi (Volumetric index) is shown in the ulna bone for the experimental right wing of the turkeys from group A, and the left wing control. The AKG treatment in control group (left wing) gives a 14.8% difference ($p < 0.01$) compared to the saline treated turkeys in BMD. In the experimental (right wing) of the group, the AKG effect is about 35.7% ($p < 0.01$) compared to the saline treated turkeys.

Conclusions

The results show the influence of AKG on the process of ulna bone mineralisation when administrated to the turkey. Also, the effect of AKG is remaining after denervation of the ulna bone.

Example 3 The effect of AKG on the bone mineralization in osteopenic female rats

15 *Objective*

The objective of this example is to study the effect of AKG after postmenopausal bone loss in rats. Ovariectomized rats are used as a preclinical animal model for human postmenopausal osteoporosis, as recommended by the US Food and Drug Administration (FDA).

20

Animals and their maintenance

60 female Wistar rats at the age of 2 months and with an initial bodyweight of 200g are used.

The animals are maintained in controlled conditions of 12/12h dark/light ratio at 22°C ± 2 and at 55% ± 2 humidity with free access to food and water.

25

Experimental design

The rats are divided into three groups ($n=20$), where Group 1 is shame operated, Group 2 is ovariectomized and Group 3 is intact, i.e. not operated at all.

30

Experimental performance

On the day of surgery, all rats are anaesthetised with an intramuscular injection of ketamine and xylaline.

20 of the rats are sham-operated (SHO), where the ovaries are exteriorised and replaced intact.

The second group of ovariectomized rats (OVX) are submitted to ovariectomy from a dorsal approach.

Six months after ovariectomy, the animals from group 1 and 2, are divided into two additional sub-groups; one placebo and one experimental group.

The content of placebo and experimental drinking water is shown in table 12.

Table 12 Content of placebo and experimental drinking water

Drink components ^c	Placebo drink ^a	Experiment drink ^b
AKG	-	146g
Glucose	300g	300g
Sucrose	150g	150g
NaOH	36g	36g
KOH	7.5g	7.5g
Ca(OH) ₂	4.6g	4.6g
Mg(OH) ₂	1.8g	1.8g
HCl	75ml	-

^a without AKG

^b with AKG

^c all components are dissolved in 10 l of distilled water, pH 4.6

After 60 days with placebo and experimental drinking water the rats are anaesthetised in CO₂ and femur isolated for further analysis of bone mineral density.

20 Results

Figure 15 shows the bone mineral density in intact (INT), SHO operated and OVX operated rats fed with or without AKG using the drinking water described in Table 12. In all three experimental groups (INT, SHO, OVX), the AKG treated animals shows a higher BMD after AKG treatment with a difference of about 10% between the AKG treated rats and the placebo treated rats ($p < 0.01$ in all groups).

Conclusions

AKG has an effect on ovariectomized rats and increases the BMD to a similar extent as in intact or sham-operated mice.

5 Example 4 The effect of AKG on growth and bone mineralisation

Objective

The objective of this example is to study the effect of AKG on growth and bone mineralization of the skeletal system during the postnatal life of the pig.

10

Animals and their maintenance

As in Example 1.

Experimental design

15 As in Example 1.

Experimental performance

Bone mineral density (BMD) was analysed by DEXA (Dual Energy X-ray Absorptiometry) using LUNAR apparatus. The method is performed according to
20 Hansen et al. in "Dual-energy x-ray absorptiometry: a precise method of measuring bone mineral density in the lumbar spine (J. Nucl. Med. (1990) 31: 1156-1162), incorporated herein by reference.

17-beta-estradiol and calcitonin was measured using RIA (Radio-Immuno Assay) using commercially available kits from Orion (Finland), and Diagnostic
25 Systems Laboratories (Webster, TX, USA) respectively.

Results

Figure 16 shows the effect of oral administration of AKG on the gain of bodyweight between the AKG treated and Ala-Gln treated groups during the first 47
30 days of postnatal life. The control group is not shown, but is always less than the Ala-Gln treated groups at the different timepoints measured. On day three, the difference is about 96g, on day 14 about 690g, on day 21 about 419g, and on day 35 about 313g. The absolute values of the bodyweight in g is shown below the bars.

Figure 17 shows the bone mineral density (BMD) of the right femur at the
35 proximal and distal metaphysis at 21 days of postnatal life.

Figure 18 shows the bone mineral density (BMD) of the right femur at the proximal and distal metaphysis at 35 days of postnatal life.

Figure 19 shows the effect of AKG administration on the level of 17- β -estradiol in blood plasma of piglets measured after 3 days, 28 days, 35 days, 56 days

and 70 days. The absolute values of 17- β -estradiol in pg/ml is shown below each bar.

Figure 20 shows the effect of AKG administration on the level of osteocalcin in blood plasma of piglets measured after 3 days, 28 days, 35 days, 56 days and 70 days. The absolute values of osteocalcin in ng/ml is shown below each bar.

Figure 21 shows the effect of Ala-Gln administration on the level of 17- β -estradiol in blood plasma of piglets measured after 3 days, 28 days, 35 days, 56 days and 70 days. The absolute values of 17- β -estradiol in pg/ml is shown below each bar.

Figure 22 shows the effect of Ala-Gln administration on the level of osteocalcin in blood plasma of piglets measured after 3 days, 28 days, 35 days, 56 days and 70 days. The absolute values of osteocalcin in ng/ml is shown below each bar.

15 Conclusions

The bodyweight of the piglets receiving AKG was more dramatic ($p > 0.01$ in comparison to Ala-Gln), than the control group as well as the group receiving Ala-Gln.

Further, the bone mineralisation in piglets receiving AKG was higher than in piglets receiving placebo.

17- β -estradiol and osteocalcin is a measure of maturation and bone formation.

Example 5 The effect of AKG on bone mineralisation in humans

25 Objective

The objective of this example is to study the effect of AKG on bone mineralization of the skeletal system in postmenopausal women with decreased bone mineral density (osteopenia).

30 Study group of postmenopausal women

64 postmenopausal women aged 45-60 years with decreased bone mineral density (osteopenia).

Experimental design

35 The study group is randomised in a double blind, parallel group. The patients are randomised to two groups where A) is given AKG + Ca and B) is given placebo + Ca as shown in table 13.

Tablets are given for 24 weeks and the dose stable during the study time, i.e. 6g of AKG + 1.68g Ca daily or placebo + 1.68g Ca daily.

All patients will take chewable tablets three times daily; during breakfast, lunch and dinner, where each tablet comprises 1g AKG + 0.28g Ca or placebo + 0.28g Ca. The tablets should be chewed and be taken just before intake of the meal.

Table 13

Study group	Daily drug dosage (amount)
A	AKG (6g) + Ca (1.68g) ^a
B	Placebo + Ca (1.68g) ^a

5 ^a Vehiculum: Corn starch and microcrystalline cellulose

Results

Serum levels of osteocalcin and CTX is used as bone turnover markers and measured by Enzyme Linked Immunosorbent Assay (ELISA). Bone mineral density
10 is measured by Dual Energy X-ray Absorptionmetry (DEXA, DPX, LUNAR Corp., USA) technique in lumbar spine.

The above outlined experimental design has in our hands proven successful in humans.

CLAIMS

1. A method for obtaining improved bone quality in a vertebrate, including mammal and bird, the method comprising administering to a vertebrate, including
5 mammal and bird, in a sufficient amount and/or at a sufficient rate to enable a desired effect, glutamate, glutamate derivatives or metabolites, glutamate analogues or mixtures thereof.
2. The method according to claim 1, wherein the glutamate, glutamate derivatives
10 or metabolites, glutamate analogues or mixtures thereof are selected from the group consisting of glutamate, alpha-ketoglutaric acid (AKG), ornitine-AKG, arginine-AKG, glutamine-AKG, glutamate-AKG, leucine-AKG and other salts of AKG with amino acids and amino acids derivatives; mono- and di-metal salts of AKG such as CaAKG, NaAKG; mono- and di-metal salts of glutamate such as Ca-glutamate, Na-
15 glutamate; glutamate dipeptides and oligopeptides e.g., L-alanyl-L-glutamate, glycyl-L-glutamate and other peptides of glutamate with amino acids; glutamate dipeptides and oligopeptides e.g., glutamate-glutamine and other peptides of glutamate with other amino acids; glutamate polymers.
- 20 3. The method according to any of claims 1-2, wherein the vertebrate is a rodent, such as a mouse, rat, guinea pig, or a rabbit; a bird, such as a turkey, hen, chicken or other broilers; farm animals, such as a cow, a horse, a pig, piglet or free going farm animals; or a pet, such as a dog, or a cat.
- 25 4. The method according to any of claims 1-2, wherein the vertebrate is a human being.
5. A method for modulating bone quality in a vertebrate, including mammal and bird, comprising administering to the vertebrate in the need thereof, glutamate,
30 glutamate derivatives or metabolites, glutamate analogues or mixtures thereof, for modulating the bone quality.
6. The method according to claim 5, wherein the glutamate, glutamate derivatives or metabolites, glutamate analogues or mixtures thereof are selected from the group
35 consisting of glutamate, alpha-ketoglutaric acid (AKG), ornitine-AKG, arginine-AKG, glutamine-AKG, glutamate-AKG, leucine-AKG and other salts of AKG with amino acids and amino acids derivatives; mono- and di-metal salts of AKG such as CaAKG, NaAKG; mono- and di-metal salts of glutamate such as Ca-glutamate, Na-glutamate; glutamate dipeptides and oligopeptides e.g., L-alanyl-L-glutamate,

glycyl-L-glutamate and other peptides of glutamate with amino acids; glutamate dipeptides and oligopeptides e.g., glutamate-glutamine and other peptides of glutamate with other amino acids; glutamate polymers.

5

7. The method according to any of claims 5-6, wherein the vertebrate is a rodent, such as a mouse, rat, guinea pig, or a rabbit; a bird, such as a turkey, hen, chicken or other broilers; farm animals, such as a cow, a horse, a pig, piglet or free going farm animals; or a pet, such as a dog, or a cat.

10

8. The method according to any of claims 5-6, wherein the vertebrate is a human being.

9. Use of glutamate, glutamate derivates or metabolites, glutamate analogues or mixtures thereof for the manufacture of a composition for the prevention, alleviation or treatment of osteoporosis.

15

10. The use according to claim 9, wherein the composition is a pharmaceutical composition with optionally a pharmaceutically acceptable carrier and/or additives.

20

11. The use according to claim 9, wherein the composition is a food or a feed supplement.

12. The use according to claim 11, wherein the food or feed supplement is a dietary supplement and/or a component in the form of solid food and/or beverage.

25

13. The use according to any of claims 9-12, wherein the glutamate, glutamate derivates or metabolites, glutamate analogues or mixtures thereof, in the manufactured composition is in a therapeutically effective amount.

30

14. The use according to claim 13, wherein the therapeutically effective amount is 0,01-0,2 g/kg bodyweight per daily dose.

15. Use of glutamate, glutamate derivates or metabolites, glutamate analogues or mixtures thereof, for the manufacture of a composition for the modulation of bone quality in a vertebrate, including mammal and bird, in the need thereof.

35

16. The use according to claim 15, wherein the composition is a pharmaceutical composition with optionally a pharmaceutically acceptable carrier and/or additives.

17. The use according to claim 15, wherein the composition is a food or a feed supplement.
18. The use according to claim 17, wherein the composition is a dietary
5 supplement and/or a component in form of solid food and/or beverage.
19. The use according to any of claims 15-18, wherein the glutamate, glutamate derivates or metabolites, glutamate analogues or mixtures thereof, in the manufactured composition is in a therapeutically effective amount.
- 10 20. The use according to claim 19, wherein the therapeutically effective amount is 0,01-0,2 g/kg bodyweight per daily dose.
21. A method for inhibition, prevention or alleviation of bone structure
15 degradation or bone weakening in a vertebrate, including mammal and bird, comprising administering to the vertebrate in the need thereof, glutamate, glutamate derivates or metabolites, glutamate analogues or mixtures thereof, for modulating the bone quality.
- 20 22. The method according to claim 21, wherein the glutamate, glutamate derivates or metabolites, glutamate analogues or mixtures thereof are selected from the group consisting of glutamate, alpha-ketoglutaric acid (AKG), ornitine-AKG, arginine-AKG, glutamine-AKG, glutamate-AKG, leucine-AKG and other salts of AKG with amino acids and amino acids derivates; mono- and di-metal salts of AKG
25 such as CaAKG, NaAKG; mono- and di-metal salts of glutamate such as Ca-glutamate, Na-glutamate; glutamate dipeptides and oligopeptides e.g., L-alanyl-L-glutamate, glycyl-L-glutamate and other peptides of glutamate with amino acids; glutamate dipeptides and oligopeptides e.g., glutamate-glutamine and other peptides of glutamate with other amino acids; glutamate polymers.
- 30 23. The method according to any of claims 21-22, wherein the vertebrate is a rodent, such as a mouse, rat, guinea pig, or a rabbit; a bird, such as a turkey, hen, chicken or other broilers; farm animals, such as a cow, a horse, a pig, piglet or free going farm animals; or a pet, such as a dog, or a cat.
- 35 24. The method according to any of claims 21-22, wherein the vertebrate is a human being.
25. Use of glutamate, glutamate derivates or metabolites, glutamate analogues or

mixtures thereof, for the manufacture of a composition for the prevention or repair of bone fractures in a vertebrate, including mammal and bird, in the need thereof.

26. The use according to claim 25, wherein the composition is a pharmaceutical
5 composition with optionally a pharmaceutically acceptable carrier and/or additives.

27. The use according to claim 25, wherein the composition is a food or a feed
10 supplement.

28. The use according to claim 27, wherein the composition is a dietary
supplement and/or a component in form of solid food and/or beverage.

29. The use according to any of claims 25-28, wherein the glutamate, glutamate
15 derivates or metabolites, glutamate analogues or mixtures thereof, in the
manufactured composition is in a therapeutically effective amount.

30. The use according to claim 29, wherein the therapeutically effective amount
20 is 0,01-0,2 g/kg bodyweight per daily dose.

25

1/22




Figure 1 (22)




Figure 2 (22)

3/22




Figure 3 (22)




Figure 4 (22)

5/22




Figure 5 (22)

6/22




Figure 6 (22)




Figure 7 (22)

8/22




Figure 8 (22)

9/22




Figure 9 (22)




Figure 10 (22)




Figure 11 (22)

12/22




Figure 12 (22)




Figure 13 (22)

14/22





Figure 14 (22)

15/22



16/22




Figure 16 (22)

17/22




Figure 17 (22)




Figure 18 (22)

19/22




Figure 19 (22)




Figure 20 (22)




Figure 21 (22)

22/22




Figure 22 (22)

INTERNATIONAL SEARCH REPORT

International application No.

PCT/SE 02/02123

A. CLASSIFICATION OF SUBJECT MATTER

IPC7: A61K 31/198

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: A61K, A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

WPI-DATA, EPO-INTERNAL

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	Gynecological Endocrinology, Vol. 7, 1993, P. Affinito et al: "A new fluoride preparation for the prevention of postmenopausal osteoporosis: calcium monofluorophosphate", page 201 - page 205, -- -----	1-30

☐ Further documents are listed in the continuation of Box C.☐ See patent family annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

21 February 2003

Date of mailing of the international search report

25 -02- 2003

Name and mailing address of the ISA/
Swedish Patent Office
Box 5055, S-102 42 STOCKHOLM
Facsimile No. +46 8 666 02 86

Authorized officer

Susanna Lindfors
Telephone No. +46 8 782 25 00

INTERNATIONAL SEARCH REPORTInternational application No.
PCT/SE02/02123**Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)**

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 1-8 and 21-24
because they relate to subject matter not required to be searched by this Authority, namely:
Claims 1-8 and 21-24 relate to methods of treatment of the human or animal body by therapy, Rule. 39.1.(iv). Nevertheless, a search has been executed for these claims. The search has been based on the alleged effects of the compositions.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.